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Barbara Conti,* and Fiorella Belpoggi*
In 1976, a systematic andintegratedprojectoflong-term carcinogenicity bioassays began atthe Bentivoglio
Experimental Unit ofthe Bologna Institute ofOncology. The Bologna experiments proved for the firsttime
that benzene is an experimental carcinogen. These experiments demonstrated thatbenzene is carcinogenic
whenadministeredbyingestion andby inhalation andthatitcause tumors inthevarioustested animal models
(Sprague-Dawley rats, Wistar rats, Swiss mice, and RF/J mice). They also showed that benzene is a mul-
tipotential carcinogen, as itproduces avariety ofneoplasias in one ormore ofthe testedanimal models, in-
cludingZymbal glandcarcinomas, carcinomas ofthe oral cavity, nasal cavities, skin, forestomach, andmam-
mary glands, as well as angiosarcomas ofthe liver, hemolymphoreticular neplasias, tumors ofthe lung, and
possibly hepatomas. The Bolognaexperiments also indicated aclear-cut dose-response relationship in ben-
zene carcinogenesis.
This reportpresents the up-to-date results ofthe Bolognaproject. The need formore experimental research
aimed at assessing the carcinogenic effects oflow doses ofbenzene, ofchemical mixtures containing ben-
zene, and ofbenzene substitutes is emphasized. Also recommended are more comprehensive epidemiologi-
cal investigations, extended to all types ofmalignancies, with particular regard to lung carcinomas.
Introduction
Benzene has beenproducedindustrially from coal since
1849 and from petroleum since 1941. At present the
major source ofbenzene is petroleum. Benzene is one of
the largely diffused andproduced industrial compounds.
Itis a constituent ofcrude oil, itis present in gasoline and
otherfossil fuels, and itis currently produced atthe rate
ofabout 15 million tons per year(the majorproducers are
the U.S., Japan, and Western Europe). The total global
annual cycle ofbenzene is estimated tobe32 million tons
per year (1).
The major use of benzene in past was in blends with
gasoline. Although this use has been reduced in the
United States, benzene is still extensively employed in
manycountriesfortheproduction ofcommercial gasoline.
The benzene content in gasoline varies from country to
country, and its range is estimated to be from 1 to 15%.
Currently, benzene is used as a chemical intermediate for
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theproduction ofmany important industrial compounds,
such asethylbenzene (used inthe production ofstyrene),
phenol, cyclohexane, maleic anhydride, aniline, dich-
lorobenzenes, etc., which, in turn, supply numerous sec-
tors ofthe chemical industry, especially thoseproducing
plastics, resins, elastomers, dyes, and pesticides. In the
past, benzene was also used as a solvent for paints and
rubber, intheproduction ofrubbercement(widelyused
inthe shoe andgarmentindustries), andinthe manufac-
ture ofartiflcialleather. Ithas alsobeenused inmedicine
inthe treatment ofhemoblastomas(leukemias, polycyte-
mia, andmalignantlymphomas) and in veterinary medi-
cine of disinfecting wounds.
Ofthe 32 milliontons ofbenzene circulatedgloballyper
year, 4 million tons are estimated to be lost to the en-
vironment(1). Themajorsourceis motorvehicle emission
andevaporation losses duringhandling, distribution, and
storage ofpetrol(2). Burningwood andorganicmaterial
alsoresults in an appreciable releaseofbenzene. Tobacco
smoke contains benzene at levels of47 to 64 ppm (3). It
isbelieved thatplant and animalmatteralso release ben-
zene into the environment (4).
Populationgroups thatmaybe exposed to benzene in-MALTONI ETAL.
clude workers engaged in its production; workers in
chemical industries using benzene as an intermediate;
workers inindustriesproducingmaterialscontainingben-
zene as a constituent (gasoline), as a solvent (rubber ce-
ment), oras animpurity (i.e.,industrytoluene); peopleliv-
ing near factories producing or using benzene, or
compounds containing it; tobacco smokers; and the
general population (particularly in industrialized towns),
as benzene is contained ingasoline, drinking water, and
many other goods and is highly volatile.
Prolonged exposure tobenzene causestoxic effects on
bone marrow, both in animals and humans. The toxic ef-
fects on the hematopoietic system in humans have been
knownforabout90years andarewell documentedinthe
literature. The classical clinical finding in benzene
hematotoxicity is a decrease in the various formed ele-
ments of circulating blood (pancytopenia) as a conse-
quence of the decrease in identifiable granulocyte,
erythrocyte, andplateletprecursorswithin thebonemar-
row. The associationbetweenlong-termexposure toben-
zene and the occurrence of leukemia was suggested as
early as 1928by Delore and Borgomano (5), who reported
alymphoblastic leukemia in a worker who had been ex-
posed to benzene for 5 years.
In spite of its industrial importance, widespread use,
ubiquitous diffusion, the large number ofpeople poten-
tially exposed, and the early reports of occupational
leukemias, there were no adequate epidemiological inves-
tigations nor adequate experimental research onbenzene
until the mid-1970s.
Knowledge of Benzene
Carcinogenicity until the Mid-1970s
Human data are based, almost exclusively, onreports
of a series of clinical cases ofleukemia (generally in in-
dividuals with ahistory ofbenzene myelotoxicity) and on
more indirect epidemiological investigation onthe corre-
lation between benzene exposure and the incidence of
leukemias.
Since the first report of Delore and Borgomano (5),
many leukemias in people exposed to benzene were the
subject of case reports. Vigliani in 1976 (6) stated that
it... an approximate estimation of the available litera-
ture, including some unpublished North Italian cases of
which we have knowledge, puts the number of known
cases ofleukemiaattributed tobenzene at, at least, 150."
These cases were collectedandreviewed byGoldstein(7)
(Table 1).
Acute myelogenous leukemia has been the most fre-
quent form of leukemia associated with benzene ex-
posure. Otherforms ofleukemia that have also been as-
sociated with benzene are erythroleukemia, acute
monocytic leukemia, chronic myelogenous leukemia,
myelofibrosis andmyeloidmetaplasia, thrombocytemia,
acute lymphoblastic leukemia, chroniclymphocytic leuke-
mia, and lymphomas ofvarious types.
Themajorityofthe caseshavebeenfoundin Italy(6,8),
France (9-14), and Turkey (15,16). Most ofthe cases oc-
Table 1. Case reports of hemolymphoreticular neoplasia and cor-
related diseases observed in individuals exposedto benzene reported
in scientific literature until the mid-1970s (7).
Type No. of individuals No. of reports
Acute myelogenous 58 28
leukemia
Erythroleukemia 16 10
Acute monocytic 3 2
leukemia
Chronic myelogenous 27 7
leukemia
Myelofibrosis and 7 5
myeloid metaplasia
Thrombocythemia 1 1
Acute lymphoblastic 8 4
leukemia
Chronic lymphocytic 9 7
leukemia





The variety in type and distribution of the described
leukemiasin the major case reports(with amore orless
pronounced prevalence ofacute myelogenous leukemia)
maybe due to several fattors: a)difference in levelofex-
posure; b)exposure inassociation with otheragents, with
toxic effects on hematopoietic tissues; c) individual
responsiveness; and d) differences in the morphological
interpretation of the hemopathological pictures, which
vary with time, country, and training.
Allofthepreviouslymentionedreports dealwithalim-
ited series of cases, and therefore the cases are frag-
mentedinto alarge numberofreports(Table 1). Inmost
ofthese reports, the causalrelationbetweenbenzene ex-
posure and leukemia is developed more from the history
ofthe single cases, showingcharacteristic sequence, ben-
zene exposure-myelotoxicity-leukemia, thanfrom statisti-
cal and biological evaluation.
Moreover, the indirect results ofone epidemiological in-
vestigationperformedinJapan, werereported. Ishimaru
and co-workers (17) examined 303 cases ofleukemiathat
occurred among adult survivors ofthe atomic bomb ex-
plosions at Hiroshima and Nagasaki andcompared them
with 303 matched controls exposed to the same amount
ofionizingradiationfrom the bomb. Theyfound thatthe
risk of leukemia was approximately 2.5 times higher
among those with the history ofa probable exposure to
benzene or its derivatives and to medical X-rays.
Benzene was shown to be genotoxic to human blood
cells. Increasedratesofboth stableandunstable chromo-
some changes have been describedboth inlymphocytes
andbone marrowcells ofpatients withbenzene hemopa-
thy andinlymphocytes ofworkers withpast exposure to
benzene but without signs ofpoisoning(18-24). Chromo-
some damagefrombenzene canpersistforyearsinlong-
livedlymphocytes and mayresult intheformation ofab-
normal cell clones in the absence of any sign of disease
(21,22). Increased chromosome aberrations ofblood lym-
phocyteshave alsobeenreported inworkers exposedto
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less than 25 ppm ofbenzene (25-27). There have been a
number of reports of cases of benzene pancytopenia in
which the observed bone marrow cellular atypias were
progressing toward acute leukemias.
The available experimental data prior to 1976, summa-
rized in Table 2, are scanty and insubstantial (28-31). In
IARC Monograph No. 7(32), it was concluded that "ben-
zene hasbeen tested onlyin mice by subcutaneous injec-
tion and skin application. The data reported do not per-
mit the conclusion that carcinogenic activity has been
demonstrated."
Knowledge of Benzene
Carcinogenicity from the Mid-1970s
to the Present
A systematic integrated experimental project (the
largest up to present) of long-term carcinogenicity
bioassays on benzene began in April 1976 at the Ben-
tivoglio (BT) Experimental Unit ofthe Bologna Institute
ofOncology. The project was aimed at studying the car-
cinogenic effects ofbenzene administrated by different
routes (ingestion and inhalation) at different daily
doses/concentrations on animals ofdifferent species and
strains(Sprague-Dawley andWistar rats and Swiss and
RF/Jmice) and ofdifferent ages atthe start ofthe treat-
ment. As early as November-December 1977, prelimi-
nary results were published (33) showing that benzene
wasproducingin Sprague-Dawley rats Zymbalgland car-
cinomas, an increase ofother solid tumors and amarginal
increase of malignant hemolymphoreticular neoplasias.
Since then, the dataofthisproject, have shown thatben-
zene has carcinogenic effects when given by inhalation
andbyingestion, it causestumors inalltested animal spe-
cies and strains, it is a multipotential carcinogen, as it
produces a large variety of neoplasias, and there is a
clear-cut dose-response relationship in benzene carcino-
genesis. The data have been summarized, from 1977 to
1987, in various publications (34-45).
Furtherexperimental bioassays were then performed
in otherlaboratories. Bone marrow hyperplasia, thymic
lymphoma(6/40), plasmacytoma(1/40), andleukemia(1/40)
were reported in C57BL/6Jmice exposed to air contain-
Table 2. Long-term carcinogenicity bioassays on benzene: available data until 1976.
Animals
Treatment and other
Species Strain Sex No. experimental details Results Observations Reference
Mice Albino M,F 33 Ta SC injection of 0.001 8 Leukemias (from 4-8 months No control group (28)
mL ofbenzene in from the starting of the
0.1 mL of olive oil, treatment)
once weekly, for
17-21 weeks (total
dose, about 1 mg/kg
body weight)
Mice F ? 30 T SC injection of 0.001 mL 6 Leukemias (30%) (from 200- Leukemia increase in (29)
of benzene in 0.1 mL 300 days of age) treated animals is
of sesame oil not statistically
significant
212 C 29 Leukemias (14%) (before
300 days of age)
Mice DBA2 M 30 T SC injection of 0.001 mL 0 Maximum survival of (30)
C3H 30 T of benzene in 0.1 mL 0 DBA2, C3H and
C57BL6 30 T of olive oil, for all 0 C57BL/6 mice: 730
life span days
AKR M 30 T 16 Leukemias Major survival of
(between the 7 and animals of control





35 C 30 Leukemias
Mice Swiss M,F 10 T SC injection of 0.001 mL 5 SC sarcomas (at autopsy, 2 Animals dead within (31)
ofbenzene in 0.1 mL performed between days the first 8 weeks of
of olive oil, for 162 and 253 from start of treatment
10 weeks treatment)
No control group
Mice Various M,F Very many Skin applications No effects Nonsystematic and Many
Rats non-ad hoc planned
Rabbits experiments
'T, treated; C, control.
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ing 300 ppm benzene for 6 hr/day, 5 days/week, for 488
days as compared with an incidence of2/40 lymphomas
(nonthymic) in the controls (46). Myelogenous leukemia
occurred in 2/40 CD-1 mice exposed to aircontaining300
ppmbenzene for 6hr/day, 5 days/week, forlife (47). The
results ofthese two studies, because ofthe smallnumber
ofanimals usedandthe marginalincrease ofthe observed
hemolymphoreticular neoplasias, do not allow establish-
ment ofa positive association between the onset ofthe
neoplasias and the benzene exposure.
Cronkite (48,49) showed that female mice exposed at
300ppm(6hr/day, 5days/weekfor 16weeks, afterwhich
exposures was stopped) exhibited increased incidence of
leukemias (8/88 versus 20/89)largely due to thymic lym-
phomas (1/88 versus 10/89). In addition, Zymbal gland
neoplasias (1/88 versus 16/89) and ovarian tumors (0/88
versus 8/89) were increased.
NTP performed a long-term carcinogenicity bioassay
onF344/NratsandB6C3F1 mice(50). Fiftymale andfifty
female/dose level were gavaged 5 days/week for 103
weeks. Doses of 0, 50, 100, or 200 mg/kg body weight
benzene in corn oil(5mL/kg)were administered to male
rats. Doses of0, 25, 50, or 100 mg/kg benzene in corn oil
were administeredtofemale ratsandtomale andfemale
mice. The results ofthisexperiment confirm thefindings
ofBologna-BT project, i.e., thatbenzene is amultipoten-
tial carcinogen. A definite or marginally increased inci-
dence of the following tumors was found in benzene-
exposed animals ofone orboth sexes: tumors ofZymbal
glands, oral cavity, and skin in rats; tumors of Zymbal
glands, hemolymphoreticular tissues, lungs, Harderian
glands, mammaryglands, preputial glands, forestomach,
ovary, and liver in mice.
Recentepidemiological studiesofsmallcohortsexposed
to benzene have demonstrated a causal association with
leukemia(51-58). Infante etal. (51)reportedanincreased
risk of leukemias among workers at three rubber
hydrochlorideplants(in two Ohio locations)whowere ex-
posedtobenzene inthe years 1940 to 1949. In thatinves-
tigation, the vital status of 75% of the population was
ascertained. The level of exposure was estimated to be
not greater than the standards at that time would have
allowed. Rinsky etal. (53)reported thefindings ofamore
extensiveinvestigation onthe samerubberworkers. The
major findings of this important study may be summa-
rized asfollows: a)the workerswere exposed toonly one
agent thathasbeenassociatedwithblood dyscrasias, i.e.,
benzene; b) exposure data, uncommonly complete
throughout the study period (1940-1975), indicated that
the exposures of the workers were, for the most part,
withinlimitspermissible atthetime(theselimits arenot
greatly higher than the current legal standards); and c)
the vital status (alive, dead, and cause ofdeath) for 98%
of the study population was ascertained. There were
seven deaths from leukemia (myelocytic or monocytic)
among 748 workers; this rate is 5.6-fold greater than
wouldbeexpectedinacomparable population. Forwork-
ers exposed 5 years or more, there was a 21-fold in-
creased risk ofdeath from leukemia. In 1986, Rinsky et
al. (57,58)reexamined the updated mortality onthe same
cohorts and calculated acumulativebenzene exposurein-
dex (ppm x years) for each cohort member. These
authorsfoundthatthe standardmortalityratio(SMR)for
leukemia was 328 and for multiple myeloma was 398.
With stratification ofthe cohortby cumulative exposure,
the SMRs for leukemia increased from 105 in workers
withless than40-ppmyears exposure, to 314 inworkers
with40-to 199-ppmyears, to 1757 inthosewithfrom200-
to 399-ppm years, and to 4535 in those with 400-ppm
years or more.
In 1985, Maltoni et al. reported the first experimental
evidence of the carcinogenicity of benzene-correlated
compounds, namelytolueneandxylene(44). Theseresults
hasbeenrecently confirmedbythe same authorsbyfur-
ther experiments whose results are now in publication.
The history ofbenzene carcinogenicity is summarized
in Table 3.
This report presents the up-to-date results of the ex-
periments onbenzene carcinogenicity performedbythe
Institute of Oncology of Bologna (BT experimental
project).
Materials and Methods
The plan ofthe experiments is shown in Tables 4-10.
The bioassay on RF/J Mice (Table 10) is part ofa larger
experiment aimed at studyingthe effect of10% ethyl al-
cohol, administered instead ofdrinldngwater, onbenzene
carcinogenesis (Table 11). (The results of the whole ex-
periment are nowbeing submitted forpublication.) Data
on test compounds and test animals are presented in
Table 12. Details on the conduct ofthe experiments are
as follows:
*The animals were exposed by inhalation in air, 4 to 7
hr/day, 5 days/week, for 15 and 104 weeks. The cham-
bers for inhalation exposure were stainless steel, with
two glass doors, and measured 135 x 98 x 65 cm. The
volume was 860 L. Continuous air flow provided 12 to
15 air changes per hour. Before introduction, air was
filtered and the chamberarrangementwas suchthatair
flowed from one part ofthe chamber to the otherwith-
Table 3. History ofbenzene carcinogenicity.
Year Report
1928 First report on an acute leukemia following
benzene intoxication (5)
1960s Reports of cases of leukemias among workers
(mainly shoemakers) heavily exposed to benzene,
in Italy (8)
1970s Reports of cases ofleukemias among workers
(mainly shoemakers) heavily exposed to benzene,
in Turkey (15,16)
1977 First evidence of carcinogenicity of benzene in
experimental animals (rats) (33)
1977-1983 Experimental evikence showing that benzene is a
multipotential carcinogen in rodents (rats and
mice) (43,44)
1977-1986 Epidemiological evidence of benzene leukemogeni-
city among exposed workers in the U.S., also at
low doses (51,53,57,58)
1983-1987 First experimental evidence of carcinogenicity of
benzene correlated compounds (toluene and
xylenes) (44)
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Table 4. Plan ofexperiments on benzene carcinogenicity: experiment BT 901.a
Sprague-Dawley rats, 13 weeks old at start
Group no. Dose M F Total
I 250 mg/kg body weight 35 35 70
II 50 mg/kg body weight 30 30 60
III 0 30 30 60
(Controls)b
Total 95 95 190
aExposure by ingestion (stomach tube) in olive oil, once daily, 4-5 days weekly, for 52 weeks. Duration of the biophase, life-span.
bOlive oil alone.
Table 5. Plan ofexperiments on benzene carcinogenicity: experiment BT 902.a
Sprague-Dawley rats, 7 weeks old at start
Group no. Dose M F Total
I 500 mg/kg body weight 40 40 80
II 0 50 50 100
(Controls)b
Total 90 90 180
aExposure by ingestion (stomach tube) in olive oil, once daily, 4-5 days weekly, for 104 weeks. Duration of the biophase, life-span.
bOlive oil alone.
Table 6. Plan ofexperiments on benzene carcinogenicity: experiments BT 901, BT 902.a
Sprague-Dawley rats, 7 and 13
Treatment weeks old at start
Experiment and group no. Dose Length, weeks M F Total
BT 902 500 mg/kg body weight 104 40 40 80
I
%
BT 901 250 mg/kg body weight 52 35 35 70
I
BT 901 50 mg/kg body weight 52 30 30 60
II
BT 901 0 30 30 60
III (Controls)b
BT 902 0 50 50 100
II (Controls)b
Total 185 185 370
aExposure by ingestion (stomach tube) in olive oil, once daily, 4-5 days weekly. Duration of the biophase, life-span.
bOlive oil alone.
out recirculation. The internal pressure was about 1 mm
Hg less than that of the room where the chamber was
situated, to avoid any possible contamination ofthe out-
side environment. Chambers were maintained at
210C ± 30C and at 50%± 10% relative humidity. Light-
ing was provided by room light. The chambers were
cleaned at monthly intervals. Exposure chambers were
provided with a fixed point matrix for checking the dis-
tribution ofthe test substance. During treatment the dis-
tribution was continuously monitored by gas chromato-
graphs.
*The animals were exposed by ingestion (stomach tube,
made ofstainless steel), once daily, 4 to 5 days/week, for
52 (Sprague-Dawley rats, RF/J mice), 78 (Swiss mice)
and 104 weeks (Sprague-Dawley and Wistar rats).
*All the animals were kept under observation until spon-
taneous death.
*The status and behavior ofthe animals were examined
3 times daily.
*The animals were submitted to clinical examination for
gross changes every 2 weeks.
*The animals were weighed every 2 weeks duringtreat-
ment, and then every 8 weeks.
*Full necropsy was performed on all the animals; see
below.
*The housingand the diet ofthe animals were the same
adopted in the BT Experimental Unit duringthe last 15
years.
*All the experiments were performed with the same
highly standardized procedures in order to allow com-
parison.
The tissues and organs submitted to histopathological ex-
amination were thefollowing: subcutaneous lymphnodes,
brain and cerebellum, pituitary, Zymbal glands, inter-
scapular brown fat, salivary glands, Harderian glands,
oral and nasal cavities (seven sections of the head),
tongue, pharynx, thymus and mediastinal lymph nodes,
lungs, diaphragm, liver, kidneys, adrenals, spleen,
esophagus, mesenteric lymph nodes, stomach, various
segments ofthe intestine, bladder, uterus, gonads, any
other organs with pathological lesions, and, only for ex-
periment BT 909, lachrymal and preputial glands.
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Table 7. Plan ofexperiments on benzene carcinogenicity: experiments BT 4004,4006.a
Sprague-Dawley rats, 13 weeks old, breeder (B)
Treatment and 12-day embryo (E)
Group no. Concentration Schedule Age M F Total
I 200 ppm 4 hr/day, 5 days/week, B 54d 54
7 weeks (22)e
7 hr/day, 5 days/week,
12 weeks
300 ppm 7 hr/day, 5 days/week,
85 weeksb
II 200 ppm 4 hr/day, 5 days/week, E 75 65 140
7 weeks
7 hr/day, 5 days/week,
12 weeks
300 ppm 7 hr/day, 5 days/week,
85 weeksb
III 200 ppm 4 hr/day, 5 days/week, E 70 59 129
7 weeks
7 hr/day, 5 days/week,
8 weeksc
IV 0 B 60d 60
(Controls) (24)e
V 0 E 158 149 307
(Controls)
Total 303 387 690
aExposure by inhalation for 15 and 104 weeks. The embryos were exposed transplacentally during pregnancy, and the offspring were exposed
concurrently during weaning by inhalation and possibly by ingestion via milk.
bTotal period of exposure, 104 weeks.
cTotal period of exposure, 15 weeks.
dTotal breeders.
ePregnant breeders. Table 10. Plan ofexperiments on benzene carcinogenicity:
experiment BT 909.a
Table 8. Plan ofexperiments on benzene carcinogenicity:
experiment BT 907.a
Wistar rats, 7 weeks
old at start
Group no. Dose M F Total
I 500 mg/kg body weight 40 40 80
II 0 40 40 80
(Controls)"
Total 80 80 160
aExposure byingestion (stomach tube) in olive oil, once daily, 4-5 days
weekly, for 104 weeks. Duration of the biophase, life-span.
bOlive oil alone.
Table 9. Plan of experiments on benzene carcinogenicity:
experiment BT 908.a
Swiss mice, 7 weeks
old at start
Group no. Dose M F Total
I 500 mg/kg body weight 40 40 80
II 0 40 40 80
(Controls)b
Total 80 80 160
aExposurebyingestion (stomachtube), in olive oil, once daily, 4-5 days
weekly, for 78 weeks. Duration of the biophase, life-span.
bOlive oil alone.
RF/J mice, 6 weeks
old at start
Group no. Dose M F Total
I 500 mg/kg body weight 45 40 85
II 0 45 40 85
(Controls)'
Total 90 80 170
aExposurebyingestion(stomachtube), in olive oil, once daily, 4-5days
weekly, for 52 weeks. Duration of the biophase, life-span.
bOlive oil alone.
Table 11. Plan ofexperiments on benzene carcinogenicity:
experiment BT 909.a
RF/J mice, 6 weeks old
at start
Group no. Treatment M F Total
I Benzene 500 mg/kg 45 40 85
body weight in oil
Ethyl alcoholb
II Benzene 500 mg/kg 45 40 85
body weight in oil
Drinking water
III Olive oil 45 40 85
Ethyl alcohol
IV Ethyl alcohol 45 40 85
V Olive oil 45 40 85
Drinking water
VI Drinking water 45 40 85
Total 270 240 510
aStudy on the effect ofethyl alcohol administration in drinkingwater
on carcinogenic effect ofbenzene givenby ingestion (stomach tube), in
olive oil, for 52 weeks. Duration of the biophase, life-span.
bEthyl alcohol instead of drinking water.
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Table 12. Test compound and test animals.
Test
compound Purity Vehicle Test animals
Benzene 99.93% (Ingestion experiments) extra-virgin olive Male and female Sprague-Dawley rats 7, 13 weeks old, and 12-day
Paraffin 0.06% oil, with no detectable levels of pesti- embryos at start of the experiments
Toluene 0.01% cides, supplied by Olearia Toscana. Male and female Wistar rats, 7 weeks old at start of the experiment
Male and female Swiss mice, 7 weeks old at start of the experiment
Male and female RF/J mice, 6 weeks old at start of the experiment
Rats (Sprague-Dawley, Wistar) and mice (Swiss) were of the breed
currently used in the BT Experimental Unit for many years. The
RF/J mice were supplied by Jackson Laboratory
Results
Experiment on Sprague-Dawley Rats
(Tables 13-25)
The most frequent tumors inthis strain ofrats, onthe
basis ofthe literature andofthe historical controls ofthe
BT Experimental Unit, are mammary tumors, malig-
nant hemolymphoreticular neoplasias (leukemias),
pheochromocytomas, and pheochromoblastomas. More-
over a variety ofother miscellaneous tumors were also
observed (59).
The administration of benzene by ingestion is associ-
atedwith an increase oftotal malignant tumors and car-
cinomas ofthe Zymbalglands(with sebaceous and squa-
mous patterns), oral cavity, nasal cavities, skin (of
different histotypes), forestomach (together with an in-
crease ofacanthomas and dysplasias), and withliver an-
giosarcomas, and amarginalincrease ofcarcinomasofthe
mammary glands, hepatomas, and leukemias.
The administration ofbenzene by inhalation is associ-
atedwith an increase oftotal malignant tumors and car-
cinomas ofthe Zymbal glands and oral cavity, and with
a marginal increase of carcinomas ofthe nasal cavities,
mammary glands, and hepatomas.
Table 13. Experiment BT 901: incidence oftotal tumors in Sprague-Dawley ratsexposedtobenzenebyingestion (stomach tube) for52 weeks.
% ofanimals
Animals bearing tumors No. of malignant
Group no. Dose, mg/kg Sex No. at start TBMTa MTb tumors per 100 animals
I 250 M 35 37.1 20.0 22.8
F 35 65.7 42.8 60.0
M+F 70 51.4 31.4 41.4
II 50 M 30 33.3 3.3 3.3
F 30 76.7 30.0 33.3
M+F 60 55.0 16.7 18.3
III Olive oil M 30 23.3 3.3 3.3
(Controls) F 30 60.0 23.3 23.3
M+F 60 41.7 13.3 13.3
aTotal benign and malignant tumors.
bMalignant tumors.
Table 14. Experiment BT 901: incidence of mammary tumors, leukemias, pheochromocytomas, and pheochromoblastomas
in Sprague-Dawley rats exposed to benzene by ingestion (stomach tube) for 52 weeks.
% of animals bearing tumors
Mammary
Animals tumors Pheochromo- Pheochromo-
Group no. Dose, mg/kg Sex No. at start BMT MTb Leukemias cytomas blastomas
I 250 M 35 5.7 - 11.4 2.9
F 35 45.7 20.0 2.9 2.9
M+F 70 25.7 10.0 7.1 2.9
II 50 M 30 20.0 - - - -
F 30 73.3 13.3 6.7 3.3 -
M+F 60 46.7 6.7 3.3 1.7 -
III Olive oil M 30 3.3 - - 3.3
(Controls) F 30 53.3 13.3 3.3 3.3
M+F 60 28.3 6.7 1.7 3.3 -
aBenign and malignant tumors.
bMalignant tumors (carcinomas, carcinosarcomas).
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Table 15. Experiment BT 901: incidence ofZymbal gland carcinomas, auricolar duct carcinomas, nasal cavities carcinomas,
and oral cavity carcinomas in Sprague-Dawley rats exposed to benzene by ingestion (stomach tube) for 52 weeks.
Animals % of animals bearing tumors
Zymbal gland Auricolar duct Nasal cavity Oral cavity
Group no. Dose, mg/kg Sex No. at start carcinomas carcinomas carcinomas carcinomas Total
I 250 M 35 - - - - -
F 35 22.9 - - 5.7 28.6
M+F 70 11.4 - - 2.9 14.3
II 50 M 30 - - - - -
F 30 6.7 - - - 6.7
M+F 60 3.3 - - - 3.3
III Olive oil M 30 - - - - -
(Controls) F 30
M+F 60 - - - - -
Table 16. Experiment BT 902: incidence oftotal tumors in Sprague-Dawley rats exposed to benzene by ingestion (stomach tube) for 104 weeks.
% of animals
Animals bearing tumors No. of malignant
Group no. Dose, mg/kg Sex No. at start TBMTa MTb tumors per 100 animals
I 500 M 40 92.5 90.0 170.0
F 40 92.5 87.5 147.0
M+F 80 92.5 88.7 158.7
II Olive oil M 50 58.0 24.0 24.0
(Controls) F 50 60.0 20.0 22.0
M+F 100 59.0 22.0 23.0
aTotal benign and malignant tumors.
bMalignant tumors.
Table 17. Experiment BT 902: incidence ofmammary tumors, leukemias, pheochromocytomas, and pheochromoblastomas
in Sprague-Dawley rats exposed to benzene by ingestion (stomach tube) for 104 weeks.
% of animals bearing tumors
Mammary
Animals tumors Pheochromo- Pheochromo-
Group no. Dose, mg/kg Sex No. at start BMTa MTb Leukemias cytomas blastomas
I 500 M 40 7.5 - 2.5 10.0 2.5
F 40 32.5 17.5 7.5 5.0 -
M+F 80 20.0 8.8 5.0 7.5 1.3
II Olive oil M 50 4.0 - 6.0 40.0 -
(Controls) F 50 42.0 14.0 2.0 22.0
M+F 100 23.0 7.0 4.0 31.0 -
aBenign and malignant tumors.
bMalignant tumors (carcinomas, sarcomas).
Table 18. Experiment BT 902: incidence ofZymbal gland carcinomas, auricolar duct carcinomas, nasal cavities carcinomas,
and oral cavity carcinomas in Sprague-Dawley rats exposed to benzene by ingestion (stomach tube) for 104 weeks.
Animals % of animals bearing tumors
Zymbal gland Auricolar duct Nasal cavity Oral cavity
Group no. Dose, mg/kg Sex No. at start carcinomas carcinomas carcinomas carcinomas Total
I 500 M 40 45.0 - 7.5 52.5 105.0
F 40 40.0 - 2.5 50.0 92.5
M+F 80 42.5 - 5.0 51.2 98.8
II Olive oil M 50 2.0 - - - 2.0
(Controls) F 50 - - - - -
M+F 100 1.0 - - - 1.0
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Table 19. Experiment BT 902: incidence ofskin carcinomas in Sprague-Dawley rats exposed to benzene by ingestion (stomach tube)
for 104 weeks.
Animals % of animals bearing
Group no. Dose, mg/kg Sex No. at start skin carcinomas
I 500 M 40 22.5
F 40 -
M+F 80 11.3
II Olive oil M 50
(Controls) F 50 2.0
M+F 100 1.0
Table 20. Experiment BT902: incidence ofhepatic tumors in Sprague-Dawley ratsexposedto benzeneby ingestion (stomach tube) for 104 weeks.
Animals % of animals bearing hepatic tumors
Group no. Dose, mg/kg Sex No. at start Hepatomas Angiosarcomas
I 500 M 40 7.5 5.0
F 40 2.5 7.5
M+F 80 5.0 6.2
II Olive oil M 50 6.0
(Controls) F 50
M+F 100 3.0
Table 21. Experiment BT 902: incidence offorestomach lesions in Sprague-Dawley rats exposed to benzene by ingestion (stomach tube) for
104 weeks.
Animals % of animals bearing forestomach lesions
Acanthomas and In situ Invasive
Group no. Dose, mg/kg Sex No. at start dysplasias carcinomas carcinomas
I 500 M 40 25.0 - 2.5
F 40 17.5 15.0 -
M+F 80 21.3 7.5 1.3
II Olive oil M 50 - -
(Controls) F 50
M+F 100 -
Table 22. Experiments BT4004,4006: incidence oftotal tumors in Sprague-Dawley ratsexposed tobenzeneby inhalation for 15 and 104 weeks.
% of animals
Treatment Animals bearing tumors No. ofmalignant
Group no. Concentration, ppm Schedule Agea Sex No. at start TBMTb MTC tumors per 100 animals
I 200 4 hr/day, 5 days/week, B F 54 70.4 27.8 29.6
7 weeks
7 hr/day, 5 days/week,
12 weeks
300 7 hr/day, 5 days/week,
85 weeks
II 200 4 hr/day, 5 days/week, E M 75 56.0 30.7 37.3
7 weeks F 65 78.5 58.5 78.5
7 hr/day, 5 days/week, M+F 140 66.4 43.6 56.4
12 weeks
300 7 hr/day, 5 days/week,
85 weeks
III 200 4 hr/day, 5 days/week, E M 70 52.8 28.6 31.4
7 weeks F 59 78.0 45.8 50.8
7 hr/day, 5 days/week, M+F 129 64.3 36.4 40.3
8 weeks
IV 0 B F 60 58.3 15.0 16.7
(Controls)
V 0 E M 158 44.9 17.1 18.3
(Controls) F 149 78.5 17.4 17.4
M+F 307 61.2 17.3 17.9
aB, breeders, E, embryos.
bTotal benign and malignant tumors.
cMalignant tumors.MALTONI ETAL.
Table 23. Experiments BT 4004,4006: incidence ofmammary tumors, leukemias, pheochromocytomas, and pheochromoblastomas
in Sprague-Dawley rats exposed to benzene by inhalation for 15 and 104 weeks.
% of animals bearing tumors
Mammary
Treatment Animals tumors Pheochromo- Pheochromo-
Group no. Concentration, ppm Schedule Agea Sex No. at start BMTb MTC Leukemias cytomas blastomas
I 200 4 hr/day, 5 days/week, B F 54 55.5 11.1 - 7.4
7 weeks
7 hr/day, 5 days/week,
12 weeks
300 7 hr/day, 5 days/week,
85 weeks
II 200 4 hr/day, 5 days/week, E M 75 8.0 - 8.0 8.0 1.3
7 weeks F 65 53.8 13.8 - 6.1 1.5
7 hr/day, 5 days/week, M+F 140 29.3 6.4 4.3 7.1 1.4
12 weeks
300 7 hr/day, 5 days/week,
85 weeks
III 200 4 hr/day, 5 days/week, E M 70 11.4 - 5.7 20.0 2.9
7 weeks F 59 62.1 13.6 6.8 8.5 -
7 hr/day, 5 days/week, M+F 129 34.1 6.2 6.2 14.7 1.6
8 weeks
IV 0 B F 60 40.0 3.3 3.3 18.3 -
(Controls)
V 0 E M 158 7.0 1.9 7.6 20.2 0.6
(Controls) F 149 56.4 5.4 0.7 18.8 0.7
M+F 307 30.9 3.6 4.2 20.8 0.6
aB, breeders, E, embryos.
bBenign and malignant tumors.
cMalignant tumors (carcinomas, sarcomas).
Table 24. Experiments BT 4004,4006: incidence of Zymbal gland carcinomas, auricolar duct carcinomas, nasal cavities carcinomas,
and oral cavity carcinomas in Sprague-Dawley rats exposed to benzene by inhalation for 15 and 104 weeks.
Treatment Animals % of animals bearing tumors
Zymbal gland Auricolar duct Nasal cavity Oral cavity
Group no. Concentration, ppm Schedule Agea Sex No. at start carcinomas carcinomas carcinomas carcinomas Total
I 200 4 hr/day, 5 days/week, B F 54 5.5 - 1.8 3.7 11.1
7 weeks
7 hr/day, 5 days/week,
12 weeks
300 7 hr/day, 5 days/week,
85 weeks
II 200 4 hr/day, 5 days/week, E M 75 8.0 - 1.3 1.3 10.7
7 weeks F 65 12.3 - 3.1 15.4 30.8
7 hr/day, 5 days/week, M+F 140 10.0 - 2.1 7.9 20.0
12 weeks
300 7 hr/day, 5 days/week,
85 weeks
III 200 4 hr/day, 5 days/week, E M 70 5.7 - 1.4 2.8 10.0
7 weeks F 59 1.7 - 1.7 10.2 13.6
7 hr/day, 5 days/week, M+F 129 3.9 - 1.6 6.2 11.6
8 weeks
IV 0 B F 60 1.7 - - - 1.7
(Controls)
V 0 E M 158 1.3 - - - 1.3
(Controls) F 149 - - -
M+F 307 0.7 - - - 0.7
'B, breeders, E, embryos.
118BENZENE: AN EXPERIMENTAL MULTIPOTENTIAL CARCINOGEN
Table 25. Experiments BT4004,4006: incidence ofhepatic tumors in Sprague-Dawley ratsexposed to benzene by inhalation for 15 and 104 weeks.
Treatment Animals % of animals bearing tumors
Group no. Concentration, ppm Schedule Agea Sex No. at start Hepatomas Angiosarcomas
I 200 4 hr/day, 5 days/week, B F 54 1.8
7 weeks
7 hr/day, 5 days/week,
12 weeks
300 7 hr/day, 5 days/week,
85 weeks
II 200 4 hr/day, 5 days/week, E M 75 2.7
7 weeks F 45 10.8
7 hr/day, 5 days/week, M+F 140 6.4
12 weeks
300 7 hr/day, 5 days/week,
85 weeks
III 200 4 hr/day, 5 days/week, E M 70 2.8
7 weeks F 59 8.5
7 hr/day, 5 days/week, M+F 129 5.4
8 weeks
IV 0 B F 60 -
(Controls)
V 0 E M 158 0.6
(Controls) F 149 -
M+F 307 0.3
aB, breeders, E, embryos.
Experiment on Wistar Rats (Tables 26-28)
The most frequently expected tumors in this strain of
rats, on the basis of the literature and of the historical
controls of the BT Experimental Unit, are mammary
tumors, leukemias, pheochromocytomas, and pheochrom-
oblastomas. Moreover, a variety of other miscellaneous
tumors were also observed (59).
The administration ofbenzene by ingestion is associ-
ated with an increase oftotalmalignant tumors and car-
cinomas ofZymbalglands, oral cavity, andnasal cavities.
Table 26. Experiment BT 907: incidence oftotal tumors in Wistar rats exposed to benzene by ingestion (stomach tube) for 104 weeks.
No. of animals
Animals bearing tumors No of malignant
Group no. Dose, mg/kg Sex No. at start TBMTa MTb tumors per 100 animals
I 500 M 40 57.5 47.5 60.0
F 40 67.5 52.5 70.0
M+F 80 62.5 50.0 65.0
II Olive oil M 40 75.0 20.0 25.0
(Controls) F 40 85.0 25.0 30.0
M+F 80 80.0 22.5 27.5
aTotal benign and malignant tumors.
bMalignant tumors.
Table 27. Experiment BT 907: incidence of mammary tumors, leukemias, pheochromocytomas and pheochromoblastomas
in Wistar rats exposed to benzene by ingestion (stomach tube) for 104 weeks.
% of animals bearing tumors
Mammary
Animals tumors
Group no. Dose, mg/kg Sex No. at start BMTa MTb Leukemias Pheochromocytomas Pheochromoblastomas
I 500 M 40 2.5 - 5.0 2.5
F 40 42.5 5.0 10.0 - -
M+F 80 22.5 2.5 7.5 1.2 -
II Olive oil M 40 10.0 - 2.5 5.0
(Controls) F 40 55.0 7.5 7.5 5.0
M+F 80 32.5 3.7 5.0 5.0 -
aBenign and malignant tumors.
bMalignant tumors (carcinomas).
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Table 28. Experiment BT 907: incidence ofZymbal gland carcinomas, auricolar duct carcinomas, nasal cavities carcinomas,
and oral cavity carcinomas in Wistar rats exposed to benzene by ingestion (stomach tube) for 104 weeks.
Animals % of animals bearing tumors
Zymbal gland Auricolar duct Nasal cavity Oral cavity
Group no. Dose, mg/kg Sex No. at start carcinomas carcinomas carcinomas carcinomas Total
I 500 M 40 17.5 - 5.0 5.0 27.5
F 40 15.0 - 2.5 10.0 27.5
M+F 80 16.2 - 3.7 7.5 27.5
II Olive oil M 40 - - - 2.5 2.5
(Controls) F 40 - 2.5 - - 2.5
M+F 80 - 1.2 - 1.2 2.5
Experiment on Swiss Mice (Tables 29-33)
The most frequently expected tumors in this strain of
mice, on the basis ofthe literature and ofthe historical
controls ofthe BT Experimental Unit, are mammary car-
cinomas (in females), lung tumors, leukemias, and hepa-
tomas. Moreover, avariety ofothermiscellaneous tumors
were also observed (59).
The administration of benzene by ingestion is associ-
ated with an increase of total malignant tumors, carci-
nomas ofthe mammaryglands, lung tumors (adenomas,
adenomas in deviation, and adenocarcinomas), and carci-
nomas of the Zymbal glands (together with an increase
of dysplasias).
Table 29. Experiment BT 908: incidence of total tumors in Swiss mice exposed to benzene by ingestion (stomach tube) for 78 weeks.
No. of animals
Animals bearing tumors No. of malignant
Group no. Dose, mg/kg Sex No. at start TBMTa MTb tumors per 100 animals
I 500 M 40 60.0 35.0 40.0
F 40 80.0 70.0 80.0
M+F 80 70.0 52.5 60.0
II Olive oil M 40 37.5 22.5 22.5
(Controls) F 40 40.0 27.5 27.5
M+F 80 38.7 25.0 25.0
aTotal benign and malignant tumors.
bMalignant tumors.
Table 30. Experiment BT 908: incidence ofmammary carcinomas, pulmonary tumors, leukemias, and hepatomas
in Swiss mice exposed to benzene by ingestion (stomach tube) for 78 weeks.
Animals % ofanimals bearing tumors
Mammary Pulmonary
Group no. Dose, mg/kg Sex No. at start carcinomas tumors Leukemias Hepatomas
I 500 M 40 - 42.5 12.5 7.5
F 40 47.5 37.5 20.0 -
M+F 80 23.7 40.0 16.2 3.8
II Olive oil M 40 2.5 7.5 12.5 5.0
(Controls) F 40 5.0 10.0 20.0
M+F 80 3.7 8.7 16.2 2.5
Table 31. Experiment BT 908: incidence ofpulmonary lesions ofoncological interest in Swiss mice exposed to benzene
by ingestion (stomach tube) for 78 weeks.
% ofanimals bearing pulmonary lesions
Animals Adenomatous hyperplasia-
Group no. Dose, mg/kg Sex No. at start Total early adenomas Adenomas Adenomasa Adenocarcinomas
I 500 M 40 42.5 2.5 22.5 15.0 2.5
F 40 37.5 - 22.5 15.0 -
M+F 80 40.0 1.2 22.5 15.0 1.2
II Olive oil M 40 7.5 - 5.0 2.5 -
(Controls) F 40 10.0 - 10.0 -
M+F 80 8.7 - 7.5 1.2 -
aAdenomas in deviation.
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Table 32. Experiment BT 908: incidence of Zymbal gland carcinomas and correlated precancerous lesions in Swiss mice
exposed to benzene by ingestion (stomach tube) for 78 weeks.
Animals % of animals bearing lesions
Group no. Dose, mg/kg Sex No. at start Total Dysplasias Carcinomas
I 500 M 40 17.5 7.5 10.0
F 40 12.5 10.0 2.5
M+F 80 15.0 8.7 6.2
II Olive oil M 40 - - -
(Controls) F 40
M+F 80 - -
Table 33. Experiment BT 908: incidence ofhepatic tumors in Swiss mice exposed to benzene by ingestion (stomach tube) for 78 weeks.
Animals % of animals bearing hepatic tumors
Group no. Dose, mg/kg Sex No. at start Hepatomas Angiosarcomas
I 500 M 40 7.5 2.5
F 40 - -
M+F 80 3.7 1.2
II Olive oil M 40 5.0
(Controls) F 40
M+F 80 2.5 -
Experiment on RF/J Mice (Tables 34-37)
The most frequently expected tumors ofthis strain of
mice, onthe basis ofthe literature andofourexperimen-
tal experience, are mammary carcinomas, pulmonary
tumors, and leukemias. The most frequent histotype of
hemolymphoreticular malignant neoplasias are lympho-
blastic lymphosarcomas (much greater percentage) and
lymphoblastic lymphosarcomas with histocytic compo-
nent.
The administration ofbenzene by ingestion is associ-
ated with an increase of total malignant tumors, mam-
mary carcinomas, lung tumors (adenomas, adenomas in
deviation, and adenocarcinomas), and leukemias. In the
treated animals the number of pulmonary tumors per
tumor-bearing animal is greatly enhanced (Table 37).
Table 34. Experiment BT 909: incidence oftotal tumors in RF/J mice exposed to benzene by ingestion (stomach tube) for 52 weeks.
No. of animals
Animals bearing tumors No of malignant
Group no. Dose, mg/kg Sex No. at start TBMTa MTb tumors per 100 animals
I 500 M 45 73.3 57.8 60.0
F 40 85.0 75.0 85.0
M+F 85 78.8 65.9 71.8
II Olive oil M 45 40.0 42.2 44.4
(Controls) F 40 50.0 37.5 37.5
M+F 85 44.7 40.0 41.2
aTotal benign and malignant tumors.
bMalignant tumors.
Table 35. Experiment BT 909: incidence of mammary carcinomas, pulmonary tumors, leukemias, and hepatomas in RF/J mice
exposed to benzene by ingestion (stomach tube) for 52 weeks.
Animals % of animals bearing tumors
Mammary Pulmonary
Group no. Dose, mg/kg Sex No. at start carcinomas tumors Leukemias Hepatomas
I 500 M 45 - 51.1 57.8 -
F 40 22.5 45.0 60.0 -
M+F 85 10.6 48.2 58.8 -
II Olive oil M 45 - 11.1 37.8
(Controls) F 40 2.5 7.5 35.0
M+F 85 1.2 9.4 36.5
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Table 36. Experiment BT 909: incidence ofpulmonary lesions ofoncological interest in RF/J mice
exposed to benzene by ingestion (stomach tube) for 52 weeks.




Group no. Dose, mg/kg Sex No. at start hyperplasia Total early adenomas Adenomas Adenomasb Adenocarcinomas
I 500 M 45 - 51.1 2.2 20.0 28.9 -
F 40 5.0 45.0 - 30.0 7.5 2.5
M+F 85 2.4 48.2 1.2 24.7 18.8 1.2
II Olive oil M 45 2.2 11.1 - 8.9 2.2 -
(Controls) F 40 - 7.5 - 7.5 -
M+F 85 1.2 9.4 - 8.2 1.2 -
aFor each tumor only the gravest lesion was counted.
bAdenomas in deviation.
Table 37. Experiment BT 909: incidence oftotal pulmonary lesions ofoncological interest in RF/J mice
exposed to benzene by ingestion (stomach tube) for 52 weeks.




Group no. Dose, mg/kg Sex No. at start hyperplasia Total early adenomas Adenomas Adenomasb Adenocarcinomas
I 500 M 45 24.4 226.7 28.9 142.2 55.6 -
F 40 17.5 80.0 5.0 65.0 7.5 2.5
M+F 85 21.2 157.6 17.6 105.9 32.9 1.2
II Olive oil M 45 2.2 15.6 - 13.3 2.2 -
(Controls) F 40 - 10.0 - 10.0 -
M+F 85 1.2 12.9 - 11.8 1.2 -
'All different lesions present in each animal were counted.
bAdenomas in deviation.
Multipotential Carcinogenicity, particularly markedin the case ofcarcinomas ofZymbal
Dose-Response, and Effect ofAge glands, oral cavity, and nasal cavities when considered
either singularly or together (Table 39). Avarilety oftumors isassociated to benzene exposure. An enhanced carcinogenic effect of benzene was ob-
in the animals ofall tested speCieS and strainS (Table 3. served in animals on which treatment was started dur-
A dose-response relationship was seen in the experi- ing embryonal life (Table 24-28).
ment with Sprague-Dawley rats. This relation appears
Table 38. Tumor associated to benzene exposure on the basis ofthe BT experimental project.
Sprague-Dawley rat Wistar rat, Swiss mouse, RF/J mouse,
Tumors Ingestion Inhalation ingestion ingestion ingestion
Total malignant tumors + + + + +
Carcinomas of Zymbal gland + + + +
Carcinomas oforal cavity + + +
Carcinomas ofnasal cavities + (+)a +
Carcinomas of the skin +
Carcinomas ofthe forestomach +
Carcinomas of the mammary gland (+) (+) + +
Hepatomas (+) (+)
Angiosarcomas ofthe liver +
Hemolymphoreticular neoplasias (+) +
Tumors of the lung + +
aWeak evidence.
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Table 39. Experiments BT 901, BT 902: incidence of Zymbal gland carcinomas, nasal cavities carcinomas, and oral cavities carcinomas
in Sprague-Dawley rats exposed to benzene by ingestion (stomach tube) for 52 and 104 weeks.
Treatment Animals % of animals bearingtumors
Experiment Zymbal gland Nasal cavity Oral cavity
and group no. Dose, mg/kg Length, weeks Sex No. at start carcinomas carcinomas carcinomas Total
BT 902 500 104 M 40 45.0 7.5 52.5 105.0
I F 40 40.0 2.5 50.0 92.5
M+F 80 42.5 5.0 51.2 98.8
BT 901 250 52 M 35 - - - -
I F 35 22.9 - 5.7 28.6
M+F 70 11.4 - 2.9 14.3
BT 901 50 52 M 30 - - - -
II F 30 6.7 - - 6.7
M+F 60 3.3 - - 3.3
BT 901 Olive oil 52 M 30
III (Controls) F 30
M+F 60 - - - -
BT 902 Olive oil 104 M 30 2.0 - - 2.0
II (Controls) F 30 - -
M+F 60 1.0 - - 1.0
Conclusions
The experimentsperformedatthe Bologna Institute of
Oncology on benzene carcinogenesis have shown that
benzene is a strong carcinogen on experimental animals;
itis carcinogenic onfour different types ofexperimental
animals, i.e., Sprague-Dawley andWistarrats, andSwiss
and RF/J mice. Exposure to benzene is associated with
an enhanced incidence ofavariety oftumors; therefore,
benzene mustbe considered amultipotential carcinogen.
The neoplastic response associated with benzene ex-
posure varies in the different types of tested animals.
Benzene has carcinogeniceffectswhengiven bothbyin-
halation and byingestion. The carcinogeniceffectsofben-
zene increasebyincreasingthe doses(daily dose, length
oftreatment). There is ahigh response when treatment
is started during embryonal life.
The experimental research may still improve our
knowledge of benzene carcinogenicity and correlated
problems. At present, in our opinion, the following ex-
perimental research deserves full priority: a) studies on
the carcinogenic effects ofminimal doses ofbenzene (in
the range ofthe present allowable levels), delivered by
inhalation, to large groups of animals (mega-
experiments); b)carcinogenicity studies on chemical mix-
tures containingbenzene(fuels); c)carcinogenicity studies
on chemically correlated and/or alternative compounds,
i.e., toluene, xylenes, trimethylbenzenes, ethylbenzene,
etc. Studies onthese threefields ofresearch are nowon-
going or planned at the Bologna Institute of Oncology.
Moreover, comprehensive epidemiological investigations
onpopulationgroups exposedtobenzene extendedto all
types ofmalignancies, withparticularregard to lungcar-
cinomas (on thebasis ofourrecent experimental results)
must be undertaken without delay.
This work was supported in partby EEC contract 323-79-4-ENV-I.
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